期刊
CLINICAL NUCLEAR MEDICINE
卷 48, 期 12, 页码 1086-1088出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004906
关键词
NET; octreotide; PRRT; somatostatin analogs; Lu-177-DOTATATE
This case report presents a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent peptide receptor radionuclide therapy. Despite a miscommunication in scheduling, the tumoral uptake was not reduced after the fourth cycle of therapy, suggesting that stopping somatostatin analogs before the therapy may not be necessary.
We present a case of a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent 4 cycles of peptide receptor radionuclide therapy with Lu-177-DOTATATE. For his first 3 cycles, therapy was performed approximately 4 weeks after his last dose of octreotide LAR. Because of miscommunication in scheduling, his fourth cycle was performed only 48 hours after his last full dose of octreotide LAR. Despite this, we found that the tumoral uptake was not reduced at all, which may add to the increasing evidence on the nonnecessity of stopping somatostatin analogs before peptide receptor radionuclide therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据